You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, January 2007
|
| DOI | 10.1158/1535-7163.mct-06-0039 |
| Pubmed ID | |
| Authors |
Natalya M Kogan, Michael Schlesinger, Esther Priel, Ruth Rabinowitz, Eduard Berenshtein, Mordechai Chevion, Raphael Mechoulam |
| Abstract |
Anthracyclines, a large group of quinonoid compounds, are used to treat some forms of cancer. Although highly effective in cancer therapy, the mechanism of action of these compounds is not specific; they act on cancer and other cells by numerous mechanisms. A new anticancer quinone (HU-331) was synthesized from cannabidiol. It shows significant high efficacy against human cancer cell lines in vitro and against in vivo tumor grafts in nude mice. In this study, we investigated its mode of action and present evidence on its unique mechanism. HU-331 does not cause cancer cell cycle arrest, cell apoptosis, or caspase activation. HU-331-caused cell death of human cancer cell lines is not mediated by reactive oxygen intermediates/species, as exposure to HU-331 failed to elicit the generation of reactive oxygen species. HU-331 inhibits DNA topoisomerase II even at nanomolar concentrations but has only a slight nonsignificant effect on DNA topoisomerase I action. The cannabinoid quinone HU-331 is a highly specific inhibitor of topoisomerase II, compared with most known anticancer quinones. It might represent a new potent anticancer drug. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 21% |
| Austria | 1 | 5% |
| Canada | 1 | 5% |
| Russia | 1 | 5% |
| Unknown | 12 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 89% |
| Scientists | 1 | 5% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Costa Rica | 1 | 1% |
| India | 1 | 1% |
| Spain | 1 | 1% |
| United Kingdom | 1 | 1% |
| Unknown | 89 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 19 | 20% |
| Researcher | 12 | 13% |
| Student > Bachelor | 10 | 11% |
| Student > Master | 7 | 7% |
| Professor | 6 | 6% |
| Other | 15 | 16% |
| Unknown | 26 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 16 | 17% |
| Medicine and Dentistry | 12 | 13% |
| Biochemistry, Genetics and Molecular Biology | 10 | 11% |
| Agricultural and Biological Sciences | 9 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Other | 11 | 12% |
| Unknown | 32 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 195. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2023.
All research outputs
#207,062
of 25,721,020 outputs
Outputs from Molecular Cancer Therapeutics
#25
of 4,088 outputs
Outputs of similar age
#409
of 174,565 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 75 outputs
Altmetric has tracked 25,721,020 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,088 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,565 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.